Literature DB >> 3105443

Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants.

S Likitnukul, G H McCracken, N Threlkeld, A Darabi, K Olsen.   

Abstract

Aztreonam (30 mg/kg) was administered intravenously every 12 h during week 1 and every 8 h during weeks 2 to 4 of life to 26 low-birth-weight (less than 2,000 g) infants, and plasma concentration-time curves were measured on two occasions. The pharmacokinetics were described equally well by one-compartment and noncompartment models, and the values on day 1 were similar to those measured during the steady state on days 3 to 6. The mean peak plasma concentrations at completion of the 10-min infusion were from 65 to 83 micrograms/ml, the higher concentrations being seen in the larger infants. The half-lives of aztreonam ranged from 5.4 to 8.6 h and did not change significantly with birth weight. The median peak and trough plasma bactericidal titer against a strain of Escherichia coli (MBC, 10 micrograms/ml) was 1:16. Against a strain of Pseudomonas aeruginosa (MBC, 16 micrograms/ml), the median peak and trough bactericidal titers were 1:8 to 1:16 and 1:4, respectively. The urinary concentrations of aztreonam on day 1 of therapy were from 24 to 460.7 micrograms/ml (mean +/- 1 standard deviation, 254 +/- 113 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105443      PMCID: PMC174656          DOI: 10.1128/AAC.31.1.81

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Serial dilution antibiotic sensitivity testing with the microtitrator system.

Authors:  J H Marymont; R M Wentz
Journal:  Am J Clin Pathol       Date:  1966-05       Impact factor: 2.493

2.  Comparative in vitro study of SQ26,776.

Authors:  V Fainstein; S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

3.  Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.

Authors:  G H McCracken; Y Sakata; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Evaluation of aztreonam in experimental bacterial meningitis and cerebritis.

Authors:  W M Scheld; J P Brodeur; J C Gratz; P Foresman; G Rodeheaver
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  Single-dose pharmacokinetics of aztreonam in pediatric patients.

Authors:  H R Stutman; M I Marks; E A Swabb
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.

Authors:  J C Mihindu; W M Scheld; N D Bolton; D A Spyker; E A Swabb; W K Bolton
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

9.  Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; T B Platt; F G Pilkiewicz; M Frantz
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

  9 in total
  7 in total

Review 1.  Antibacterial-induced nephrotoxicity in the newborn.

Authors:  V Fanos; L Cataldi
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 4.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Clinical pharmacokinetics of aztreonam. An update.

Authors:  H Mattie
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

6.  Pharmacokinetics and renal tolerance of aztreonam in premature infants.

Authors:  L Cuzzolin; V Fanos; D Zambreri; E M Padovani; G Benoni
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of aztreonam.

Authors:  H Mattie
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.